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Abstract The e¡ects of bivalent cations on heparin binding,
structure, and thrombin inhibition rates of heparin cofactor II
were examined. Zn2+ ^ and to a lesser extent Cu2+ and Ni2+ ^
enhanced the interaction between heparin cofactor II and hep-
arin as demonstrated by heparin a⁄nity chromatography and
surface plasmon resonance experiments. Metal chelate chroma-
tography and increased intrinsic protein £uorescence in the pres-
ence of Zn2+ indicated that heparin cofactor II has metal ion-
binding properties. The results are compatible with the hypoth-
esis that Zn2+ induces a conformational change in heparin co-
factor II that favors its interaction with heparin.
' 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Antithrombin III (ATIII) and heparin cofactor II (HCII)
are members of di¡erent branches of the serpin family [1,2],
which potently inactivate thrombin in the presence of heparin
[3]. Despite this shared function the inhibitors are distin-
guished by several structural and functional aspects. Throm-
bin inhibition by HCII is not markedly potentiated by the
high a⁄nity heparin pentasaccharide sequence [4] that
strongly modulates ATIII/thrombin interaction. In addition,
thrombin inhibition by HCII is accelerated by compounds [5]
which are not e¡ective with ATIII. Further di¡erences include
the reactive center sequences which play an essential role in
determining the reaction rates, and ^ in part ^ the target spec-
i¢city of serpins. Furthermore, HCII has an N-terminus en-
riched in acidic amino acids that can provide a secondary
contact site between the inhibitor and thrombin [6,7].
Heparin and heparin-like glycosaminoglycans (GAGs) rep-
resent important activators of thrombin inhibition by HCII,
thus it is of considerable interest to investigate the interactions
between the inhibitor and GAGs. The a⁄nity of HCII for
heparin seems to be modest as indicated by the low salt con-
centrations required for elution of the native inhibitor from
matrix-bound heparin under the commonly applied condi-
tions. However, various observations indicate that the intrin-
sic heparin a⁄nity of HCII may be markedly higher [8^10].
Determinants of heparin binding by HCII have been identi¢ed
in the helix A and D regions [3,11]. The intrinsic £uorescence
of HCII is barely changed upon heparin binding, while der-
matan sulfate addition results in a maximum decrease of the
£uorescence intensity of 13% with a Kd of V25 WM [12].
The interactions of heparin and other GAGs with proteins
may be complex, due to the structural diversity of either of the
interaction partners. GAGs may be modi¢ed through varia-
tions involving saccharide composition, size, extent and ster-
eochemistry of modi¢cations [13,14], resulting in selective
binding of ligands. Heparin, for instance, binds Zn2þ, while
dermatan sulfate does not [15,16], and several reports have
documented that cations may a¡ect binding of GAGs to pro-
teins [17,18], sometimes involving structural and/or functional
changes of the polypeptides.
2. Materials and methods
2.1. Materials
HiTrap Heparin HP (contains porcine heparin), and HiTrap Che-
lating HP columns were obtained from Amersham Biosciences. Chro-
mozym TH and human ATIII (5.5 U/mg) were from Roche Diagnos-
tics. Human K-thrombin (3030 NIH units/mg) and heparin from
porcine intestinal mucosa (175 USP units/mg) were from Sigma.
The streptavidin-modi¢ed sensor chip SA was purchased from BIA-
core. Biotinylated heparin from porcine intestinal mucosa (5^8 mol%
biotin) used for immobilization on chips was from Calbiochem (cat.
no. 375054).
2.2. Protein puri¢cation
Human HCII was puri¢ed from outdated citrated plasma as de-
scribed [19,20] followed by heparin a⁄nity chromatography in the
presence of 50 WM ZnCl2. HCII purity was estimated by Coomassie
brilliant blue staining after sodium dodecyl sulfate^polyacrylamide gel
electrophoresis. Protein concentrations were determined by measuring
the absorbance at 280 nm [21].
2.3. Chromatography
The relative a⁄nity of HCII for heparin was determined by fast-
protein liquid chromatography (Pharmacia Biotech). Dialyzed sam-
ples were loaded onto a 1 ml HiTrap heparin column equilibrated
in 20 mM Tris^HCl, pH 7.4 with or without bivalent cations and
eluted with a linear NaCl gradient (40 ml, 0^1 M) in the absence or
presence of bivalent cations. The NaCl concentration was determined
by on-line conductivity monitoring. Fractions of 1.5 ml were collected
and assayed for HCII by Western blotting [22].
1 ml HiTrap chelating columns were charged with 5 ml of a ZnCl2
solution (10 mM) in deionized water. After washing with deionized
water, the column was equilibrated with bu¡er A (20 mM sodium
phosphate pH 7.4, 0.5 M NaCl). Puri¢ed HCII (20 Wg) was loaded
and after washing with bu¡er A eluted with a linear imidazole gra-
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dient (30 ml, 0^150 mM). In order to monitor the imidazole concen-
tration, 0.55 M instead of 0.5 M NaCl was included in the imidazole-
containing gradient bu¡er. Control experiments con¢rmed that HCII
was not detached by the increased NaCl concentration from the col-
umn. HCII concentrations in column fractions were determined by a
sandwich-type enzyme-linked immunosorbent assay (ELISA) [22].
2.4. Surface plasmon resonance (SPR) analysis
SPR experiments were carried out at 25‡C with the aid of a BIA-
core 3000 instrument (BIAcore), monitored with the BIAcore 3000
control software (version 3.1.1), and analyzed with the BIAevaluation
software, version 3.1. Chips were pretreated with three 10 Wl injections
(10 Wl/min) of 50 mM NaOH, 1 M NaCl, and then biotinylated
heparin (60 Wl, 20 Wg/ml) in HBS-T bu¡er (10 mM HEPES, 150
mM NaCl, 0.005% Tween 20 (v/v), pH 7.4) containing 3 mM
EDTA was injected (10 Wl/min), followed by 10 Wl of 10 mM HEPES,
2 M NaCl, 0.005% Tween 20 (v/v), 3 mM EDTA, pH 7.4 (10 Wl/min).
Binding of HCII was performed in Chelex-100 pretreated bu¡er (100
Wl HBS-T; £ow rate: 20 Wl/min) in the absence or presence of metal
ions. Bu¡er £ow was maintained for 5 min after injection to allow
sample dissociation. Chips were regenerated with 50 mM HEPES, 2 M
NaCl, pH 9.5 (10 Wl). Response unit (RU) values from lanes not
exposed to biotinylated heparin were subtracted to account for non-
speci¢c HCII binding to the streptavidin surface.
2.5. Fluorescence spectroscopy
Fluorescence measurements were conducted as two-dimensional
£uorescence spectroscopy (Vex : 240^350 nm) [23]. Excitation^emission
spectra were collected at 20‡C and processed to determine the emis-
sion spectra (Vem : 240^500 nm) at the maximum excitation wave-
length (280 nm). Aliquots of a ZnCl2 stock solution were added to
the HCII sample (11 WM) to determine the relative £uorescence in-
tensity changes. The equilibrium constant was calculated by non-lin-
ear least square computer ¢t analysis from dilution-corrected data
using the equation, vI/I0 = (vI/2I0)U([HCII]0+[Zn2þ]+Kd3{([HCII]0+
[Zn2þ]+Kd)234U[HCII0] [Zn2þ]}1=2)/[HCII0] [24], assuming a stoichi-
ometry of 1.
2.6. Determination of inhibition rate constants
The stoichiometry of inhibition (SI) and second-order rate con-
stants for thrombin inhibition in the absence or presence of heparin
were determined at room temperature in 20 mM Tris^HCl, 150 mM
NaCl, 1 g/l PEG-8000, pH 7.4 [25,26] essentially as described, with a
10-fold molar excess of the inhibitors (100 nM) and Chromozym TH
as substrate.
3. Results
3.1. Heparin a⁄nity of HCII in the presence of bivalent cations
To determine whether bivalent cations a¡ect the relative
heparin a⁄nity of HCII, the e¡ects of metal ions on the
elution of the puri¢ed inhibitor from HiTrap heparin columns
were investigated. Without added bivalent cations HCII
eluted with a peak at 220 mM NaCl from the matrix (Table
1), however, inclusion of 50 WM Zn2þ caused a shift of the
peak fraction to 390 mM NaCl. Increasing the Zn2þ concen-
tration further had no signi¢cant e¡ect. Ni2þ and Cu2þ ions
also increased the heparin a⁄nity of HCII to some extent,
however, the other cations examined did not change the
HCII elution pro¢le, even if used at a concentration of
1 mM, like Ca2þ or Mg2þ, nor did these ions extinguish the
Zn2þ e¡ect. The elution properties of thrombin and ATIII
remained unchanged in the presence of Zn2þ.
3.2. E¡ect of bivalent metal ions on HCII binding to a
heparin-modi¢ed sensor chip
SPR provides a sensitive tool to analyze the interaction of
proteins with immobilized ligands, the signals of which re£ect
the amounts of polypeptide bound. Addition of puri¢ed HCII
to a heparin-modi¢ed sensor chip caused a signal that in-
creased with increasing concentrations (0.04^3 WM) of protein
applied (Fig. 1A). In the presence of 50 WM Zn2þ, the signal
was about two- to three-fold higher (depending on the HCII
concentration) than in its absence (Fig. 1B) and depended on
the Zn2þ concentration (Fig. 1C), thus indicating that Zn2þ
increased the binding capacity of the chip for HCII. Zn2þ
alone did not cause a change in RU, and the addition of
competitor heparin (30 Wg/ml) to the analyte led to almost
complete inhibition of HCII binding (not shown), indicating
that the response re£ected speci¢c interactions between HCII
and the immobilized heparin. With the exception of Cu2þ and
Ni2þ (Fig. 1D), other bivalent metal ions did not markedly
in£uence the sensorgram (not shown).
3.3. HCII is a Zn2+-binding protein
The metal ions may bind either heparin or HCII or both
molecules, to mediate the enhanced interaction. To investigate
whether HCII binds Zn2þ, the puri¢ed inhibitor (20 Wg) was
fractionated on zinc chelating Sepharose. A portion of the
protein was detected in the through-£ow, while the bound
part was eluted at V25^35 mM imidazole (Fig. 2). HCII
was also detached in the presence of 5 mM EDTA (not
shown), indicating that the protein was not bound through
interactions unrelated to metal ion complex formation.
3.4. Zn2+ enhances the intrinsic £uorescence of HCII
In order to probe the e¡ects of Zn2þ on the structure of
HCII, the intrinsic £uorescence emission of the inhibitor was
investigated (Fig. 3). On excitation at 280 nm, the emission
maximum (334 nm) was essentially unchanged upon addition
of Zn2þ, however, the £uorescence intensity was enhanced in a
concentration-dependent manner in the presence of Zn2þ with
a Kd value of V123 WM.
3.5. Rates of thrombin inactivation
In order to determine the e¡ects of Zn2þ on thrombin in-
hibition by HCII the second-order rate inhibition constants k2
were determined. Fig. 4 shows that in the presence of 50 WM
Zn2þ the rate constants were V1.5-fold lower than in its
absence over the whole range of heparin concentrations tested
with a maximum at 10 U/ml heparin in either case. The low-
ering of the rate constants was dependent on the Zn2þ con-
centration, ranging (at 2 U/ml heparin) from 1.5U108 M31
min31 in the absence of Zn2þ to 0.9U108 M31 min31 at 100
WM Zn2þ. Addition of the metal ions caused a change of the
Table 1
E¡ect of bivalent cations on the elution of HCII from HiTrap hepa-
rin column
Protein Cation Elution of peak fractions
(mM NaCl)
HCII ^ 220
50 WM Zn2þ 390
50 WM Cu2þ 270
50 WM Ni2þ 280
50 WM Mn2þ 220
1000 WM Ca2þ 220
1000 WM Mg2þ 220
50 WM Zn2þ, 1000 WM Ca2þ 390
50 WM Zn2þ, 1000 WM Mg2þ 390
ATIII ^ 760
50 WM Zn2þ 760
Thrombin ^ 470
50 WM Zn2þ 470
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SI values from V1.8 to V3.9 (not shown), suggesting that
the lowered inhibition rates in the presence of Zn2þ were due
to a shift of the partitioning of the serpin from inhibitory
activity towards substrate-like properties. A modest decrease
of the k2 values from 2.2U105 M31 min31 in the absence of
Zn2þ to 1.4U105 M31 min31 (100 WM Zn2þ) accompanied by
an increase of the SI values fromV7 toV13 was observed in
the absence of heparin. Thrombin inactivation by ATIII was
una¡ected by the metal ions regardless of the presence of
heparin, as found previously [27].
Fig. 1. SPR sensorgrams of association and dissociation between HCII and immobilized heparin. Analyte solutions containing eight di¡erent
HCII concentrations (0.04, 0.08, 0.16, 0.33, 0.75, 1.5, 2.3, and 3 WM) were perfused without (A) or with (B) 50 WM Zn2þ. The binding curves
of HCII (0.75 WM) in the presence of various concentrations of Zn2þ are shown in C. The e¡ects of di¡erent bivalent cations (50 WM each) on
the biosensor response are given in D.
Fig. 2. Fractionation of HCII by metal chelate chromatography
with a linear imidazole gradient. Column fractions (1 ml) were
probed for the presence of HCII with a sandwich-type ELISA.
Fig. 3. Intrinsic £uorescence enhancement of HCII titrated with
Zn2þ (0, 50, 100, 200, 500 and 1000 WM). The Kd value was calcu-
lated by non-linear regression analysis. a.u. = absolute units.
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4. Discussion
The data presented demonstrate that Zn2þ and to a lesser
extent Cu2þ and Ni2þ promote the interaction between HCII
and heparin. Since HCII binds to Zn2þ as indicated by metal
chelate chromatography and the metal ion-mediated changes
of its intrinsic £uorescence, the results suggest that HCII may
exist in at least two di¡erent conformations and that the metal
ions alter the inhibitor’s structure in a way that facilitates
heparin binding. Additionally, Zn2þ could make binding sites
in heparin more accessible to HCII.
There are several motifs that could mediate the interaction
of human HCII with Zn2þ. The sequence HEQVHSILH (po-
sitions 155^163) ^ variants of which are present in some of the
HCII orthologues [28,29] ^ shares similarity with Zn2þ coor-
dinating structures in a variety of proteins [27,30^32]. The
X-ray structure of native HCII [7] depicts a Ca2þ ion coordi-
nated by His290, His292, and water molecules, however, we
were unable to demonstrate an e¡ect of Ca2þ on the intrinsic
£uorescence of HCII. Less recognized is the fact that clusters
of acidic amino acids may bind Zn2þ [33,34]. Protein domains
with a large net charge tend to be £exible with low levels of
ordered secondary structure, but may adopt more rigid con-
formations in the presence of ligands [35]. The N-terminus of
HCII (positions 49^75), which includes a tryptophan residue,
is strongly enriched in acidic amino acids; in total V65% of
these residues (including two nearly quantitatively sulfated
tyrosine residues [22]) carry a negative charge and in HCII
crystals, the acidic tail is unstructured [7].
While our results demonstrate an enhancing e¡ect of Zn2þ
and some other bivalent cations on heparin/HCII interaction,
the physiological signi¢cance for this observation remains un-
clear. The free Zn2þ concentration in plasma is low [36,37],
however, a number of proteoglycans bind Zn2þ [16,38], and
some of these ^ like decorin and biglycan ^ have been pro-
posed to serve as Zn2þ storage pools potentially providing
metal ions for interaction with other proteins [16]. Zn2þ also
participates in contact activation [39] and binding of Zn2þ to
high molecular weight kininogen and factor XII may be ac-
companied by conformational changes [32,40]. Thus, the pos-
sibility that Zn2þ modulates the interaction between HCII and
heparin, heparan sulfate proteoglycans, or cell surface pro-
teins deserves further evaluation. Proteins like L-amyloid pre-
cursor protein [41], the prion protein PrP [42] and others show
enhanced binding to heparin or heparin-like GAGs in the
presence of Zn2þ and other bivalent cations. Thus these or
other proteins could compete in a metal ion-modulated man-
ner for the same targets.
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